RSS

immunotherapy combination

Results from the PANACEA study, recently presented at the San Antonio Breast Cancer Symposium, have suggested that immunotherapy may help to overcome trastuzumab-resistant breast cancer. more

News

An immunotherapy developed at Roswell Park Cancer Institute has been granted orphan drug status by the US Food and Drug Administration (FDA). more

News

Merck and Pfizer’s medication for renal cell carcinoma (RCC) is the most likely immunotherapy combination to first arrive in market, according to Global Data more

News